Study of sudden liver failure in cirrhosis patients
Part of Digestive system clinical trials.
This study looks at people with liver cirrhosis who develop a sudden, severe worsening of their liver function (called acute-on-chronic liver failure). It aims to better understand this condition and how it affects patients in the intensive care unit, which could help improve care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have liver cirrhosis (scarring of the liver).
- You must be admitted to the intensive care unit due to a sudden worsening of your liver condition.
- Your liver failure must match a specific medical definition (called ACLF).
- You must be between 16 and 70 years old.
- You must not have liver cancer or known chronic kidney disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at when liver transplant is offered and what outcomes happen in people with cirrhosis who have severe “acute-on-chronic” worsening. It may help doctors decide which patients benefit most from transplant and improve care after listing or not listing.
This trial tests a device called CytoSorb that filters the blood to reduce inflammation in patients with sudden worsening of chronic liver disease. It may help support organ function and recovery.
This study tests whether a treatment made from stem cells (cells that can help repair tissues) can improve liver function in people with a sudden worsening of long-term liver disease. The stem cells are given through a vein, and the goal is to see if they help the liver recover without needing a transplant.
This trial tests a new drug called AS1501 for people with acute-on-chronic liver failure (a sudden worsening of chronic liver disease). It aims to see if the drug can help improve liver function and reduce the need for a liver transplant. You may be eligible if you are in the early or middle stage of this condition and have a specific blood marker (high TRAIL level).
This study looks at your liver health before and after surgery to predict the risk of “acute-on-chronic liver failure,” which means a sudden worsening of liver function on top of an existing liver condition. If you qualify, your doctors may use study data to better identify who needs closer monitoring after surgery.
This trial tests whether a special type of stem cell therapy can help people with severe liver failure (called ACLF) that is not caused by a virus. The treatment may help your liver recover and improve your overall condition.
Hear when a new Acute-On-Chronic Liver Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.